GAIN THERAPEUTICS, INC Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
GAIN THERAPEUTICS, INC (GANX) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $2.20 per share as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-08-11
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $2.20.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $2.18.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $2.35.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $2.80.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $2.20 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.18 10-Q · filed 2026-05-11 |
| 2025-12-31 | $2.35 10-Q · filed 2026-08-11 |
| 2024-12-31 | $2.80 10-K · filed 2026-03-26 |
| 2023-12-31 | $3.06 10-K · filed 2025-03-27 |
| 2023-09-30 | $3.06 10-Q · filed 2023-11-14 |
| 2023-06-30 | $3.06 10-Q · filed 2023-08-10 |
| 2023-03-31 | $3.05 10-Q · filed 2023-05-12 |
| 2022-12-31 | $2.94 10-K · filed 2024-03-26 |
| 2022-09-30 | $2.93 10-Q · filed 2022-11-10 |
| 2022-06-30 | $3.32 10-Q · filed 2022-08-08 |
| 2021-12-31 | $3.46 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |